Conjugation News and Research

RSS

New research explores underlying mechanisms by which bacteria acquire antibiotic resistance genes

A scientific peek into bacteria boudoirs is revealing how "sex" among disease-causing microbes can lead different species or strains to become resistant to antibiotic medications.

18 Aug 2015

Scientists chemically synthesize ECA-derived oligosaccharides relevant for immunotherapy

Immunotherapy using monoclonal antibodies is a promising treatment strategy, and it might now be within reach: American scientists have successfully prepared an oligosaccharide enterobacterial antigen for which a monoclonal antibody has been developed. The study is published in the journal Angewandte Chemie.

31 Jul 2015

SutroVax completes $22 million Series A financing

SutroVax, a recently established biopharmaceutical vaccine company, today announced the completion of a $22 million Series A financing. SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on best-in-class conjugate vaccines, using an exclusive license to Sutro Biopharma's Xpress CF and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation respectively.

23 Jul 2015

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces it will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand.

25 Jun 2015

‘Unsurpassed protein SEC’: OMNISEC delivers accurate information with minimal sample

In a new webinar ‘Unsurpassed protein SEC using the latest innovation in advanced detection, OMNISEC’, experts from Malvern Instruments demonstrate how the OMNISEC size exclusion chromatography (SEC) system supports efficient screening early in the drug development pipeline by enabling precise characterization with minimal sample volumes.

5 Jun 2015

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.

11 Feb 2015

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.

14 Nov 2014

Children's oral language can be a good predictor of future writing difficulties

Children's future writing difficulties can be identified before they even learn how to begin writing, according to a new study by Professor Phaedra Royle and Postdoctoral fellow Alexandra Marquis of the University of Montreal's School of Speech Language Pathology and Audiology.

6 Oct 2014

Novozymes Biopharma to assess novel subunit vaccine candidate using Veltis technology

Novozymes Biopharma has entered a new collaborative research agreement with one of the world’s top vaccine companies. The partnership will enable the company to evaluate Novozymes Biopharma's modified recombinant human albumin (rAlbumin) Veltis technology, to assess the dosing and performance of a novel subunit antigen vaccine candidate.

30 May 2014

Novozymes Biopharma, ThioLogics to collaborate on drug-albumin conjugation platform

Novozymes Biopharma has entered a new collaboration with UK-based biotechnology company, ThioLogics. The collaboration brings together Novozymes' modified recombinant human albumin (rAlbumin) Veltis technology, with ThioLogics' site-specific next generation maleimide conjugation platform. This allows Novozymes to offer the pharma industry serum stable albumin drug conjugates with enhanced pharmacokinetic and/or targeting capabilities.

14 May 2014

PolyTherics extends ThioBridge antibody drug conjugate collaboration with MacroGenics

PolyTherics Limited, a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge antibody drug conjugate ("ADC") collaboration with MacroGenics Inc, a US biotechnology company developing innovative medicines utilizing its next generation antibody technologies.

11 Apr 2014

AMRI signs definitive agreement to acquire all outstanding shares of Cedarburg Pharmaceuticals

AMRI today announced that it has signed a definitive agreement to acquire all the outstanding shares of Cedarburg Pharmaceuticals, Inc. for $38.2 million in cash.

24 Mar 2014

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.

19 Dec 2013

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Ascend Biopharmaceuticals today announces that is has entered into an agreement with 3M Drug Delivery Systems to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend’s proprietary cancer vaccine technology. The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.

29 Nov 2013

Sorrento Therapeutics to acquire San Diego-based Concortis Biosystems

Sorrento Therapeutics, Inc. announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.

14 Nov 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

23 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

22 Oct 2013

Novozymes Biopharma partners with Almac to provide combined service for drug development

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, is delighted to announce its new collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

22 Oct 2013

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

Chemists at The Scripps Research Institute (TSRI) have devised a new technique for connecting drug molecules to antibodies to make advanced therapies.

8 Oct 2013

Piramal's Healthcare invests USD 2.5 million to upgrade ADC manufacturing suites

Piramal's Healthcare vertical today announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand.

26 Jul 2013

Conjugation News and Research

New research explores underlying mechanisms by which bacteria acquire antibiotic resistance genes

Scientists chemically synthesize ECA-derived oligosaccharides relevant for immunotherapy

SutroVax completes $22 million Series A financing

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

‘Unsurpassed protein SEC’: OMNISEC delivers accurate information with minimal sample

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

Children's oral language can be a good predictor of future writing difficulties

Novozymes Biopharma to assess novel subunit vaccine candidate using Veltis technology

Novozymes Biopharma, ThioLogics to collaborate on drug-albumin conjugation platform

PolyTherics extends ThioBridge antibody drug conjugate collaboration with MacroGenics

AMRI signs definitive agreement to acquire all outstanding shares of Cedarburg Pharmaceuticals

Sorrento Therapeutics acquires Concortis Biosystems

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Sorrento Therapeutics to acquire San Diego-based Concortis Biosystems

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

Novozymes Biopharma partners with Almac to provide combined service for drug development

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

Piramal's Healthcare invests USD 2.5 million to upgrade ADC manufacturing suites

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News